| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ionis Pharmaceuticals Inc (F: ISI)
ISI Technical Analysis
5
| As on 12th Dec 2025 ISI STOCK Price closed @ 66.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 38.20 & Strong Buy for SHORT-TERM with Stoploss of 32.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ISISTOCK Price
| Open | 66.90 | Change | Price | % |
| High | 66.90 | 1 Day | -0.06 | -0.09 |
| Low | 66.90 | 1 Week | -3.04 | -4.35 |
| Close | 66.90 | 1 Month | 3.04 | 4.76 |
| Volume | 10 | 1 Year | 33.09 | 97.87 |
| 52 Week High 71.56 | 52 Week Low 22.73 | ||||
F Germany Most Active Stocks
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| ISI Daily Charts |
ISI Intraday Charts |
Whats New @ Bazaartrend |
ISI Free Analysis |
|
|
ISI Important Levels Intraday
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
| RESISTANCE | 66.90 |
ISI Forecast December 2025
| 4th UP Forecast | 78.23 |
| 3rd UP Forecast | 74.6 |
| 2nd UP Forecast | 72.35 |
| 1st UP Forecast | 70.1 |
| 1st DOWN Forecast | 63.7 |
| 2nd DOWN Forecast | 61.45 |
| 3rd DOWN Forecast | 59.2 |
| 4th DOWN Forecast | 55.57 |
ISI Weekly Forecast
| 4th UP Forecast | 73.14 |
| 3rd UP Forecast | 71.14 |
| 2nd UP Forecast | 69.90 |
| 1st UP Forecast | 68.67 |
| 1st DOWN Forecast | 65.13 |
| 2nd DOWN Forecast | 63.90 |
| 3rd DOWN Forecast | 62.66 |
| 4th DOWN Forecast | 60.66 |
ISI Forecast2025
| 4th UP Forecast | 161.11 |
| 3rd UP Forecast | 130.9 |
| 2nd UP Forecast | 112.22 |
| 1st UP Forecast | 93.55 |
| 1st DOWN Forecast | 40.25 |
| 2nd DOWN Forecast | 21.58 |
| 3rd DOWN Forecast | 2.9 |
| 4th DOWN Forecast | -27.31 |
Ionis Pharmaceuticals Inc ( F Germany Symbol : ISI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ISI Business Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Address: 2855 Gazelle Court, Carlsbad, CA, United States, 92010
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service